Abstract
Palbociclib with endocrine therapy is a first line treatment for patients with estrogen receptor positive (ER+)/ human epidermal growth factor receptor negative (HER2-) metastatic breast cancer (MBC). There is limited data regarding factors which predict progression-free survival (PFS) in patients receiving this treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
